Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $14.67

Pulmonx Co. (NASDAQ:LUNG) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $14.67.

A number of equities research analysts recently commented on LUNG shares. Stifel Nicolaus decreased their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Canaccord Genuity Group boosted their target price on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Company cut their price target on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st.

Pulmonx Stock Performance

Pulmonx stock opened at $6.30 on Friday. The company has a market cap of $248.79 million, a PE ratio of -4.29 and a beta of 0.68. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx has a 1 year low of $5.46 and a 1 year high of $14.84. The company’s 50-day moving average is $6.96 and its two-hundred day moving average is $7.08.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The business had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. During the same period in the prior year, the business posted ($0.39) earnings per share. Equities analysts anticipate that Pulmonx will post -1.53 earnings per share for the current year.

Insider Buying and Selling at Pulmonx

In related news, General Counsel David Aaron Lehman sold 5,765 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total transaction of $38,567.85. Following the sale, the general counsel now directly owns 203,348 shares in the company, valued at $1,360,398.12. This trade represents a 2.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Geoffrey Beran Rose sold 4,586 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total transaction of $30,726.20. Following the completion of the transaction, the insider now directly owns 295,433 shares of the company’s stock, valued at approximately $1,979,401.10. The trade was a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 70,351 shares of company stock valued at $494,094. 5.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently bought and sold shares of the company. 272 Capital LP acquired a new stake in shares of Pulmonx in the third quarter valued at approximately $25,000. nVerses Capital LLC acquired a new stake in Pulmonx in the 3rd quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Pulmonx during the 2nd quarter worth about $37,000. SG Americas Securities LLC acquired a new position in shares of Pulmonx during the 3rd quarter worth about $102,000. Finally, Hsbc Holdings PLC bought a new position in shares of Pulmonx in the 2nd quarter valued at about $93,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.